{"gene":"PDE5A","run_date":"2026-04-29T11:37:58","timeline":{"discoveries":[{"year":1998,"finding":"Human PDE5A1 encodes an 875-amino-acid cGMP-binding, cGMP-specific 3',5'-cyclic nucleotide phosphodiesterase that hydrolyzes cGMP; this activity is inhibited by selective PDE5 inhibitors zaprinast and DMPPO, as demonstrated by expression in yeast and enzymatic assay.","method":"Heterologous expression in yeast, in vitro enzymatic assay, pharmacological inhibition","journal":"Gene","confidence":"High","confidence_rationale":"Tier 1 — reconstituted enzymatic activity in yeast, inhibitor validation, replicated across labs","pmids":["9714779"],"is_preprint":false},{"year":1998,"finding":"The human PDE5A gene contains 21 exons and maps to chromosome 4q26; its catalytic domain shows evolutionary relatedness to the rod photoreceptor phosphodiesterase beta-subunit (PDE6B) gene based on exon-intron organization comparison.","method":"Genomic library isolation, FISH chromosomal mapping, genomic structure analysis","journal":"European journal of biochemistry","confidence":"High","confidence_rationale":"Tier 1 — direct genomic sequencing and FISH, multiple orthogonal methods","pmids":["9716380"],"is_preprint":false},{"year":2002,"finding":"The human PDE5A gene encodes three isoforms (PDE5A1, PDE5A2, PDE5A3) from two alternative promoters; the upstream promoter drives all three isoforms while an intronic promoter drives only PDE5A2. Both promoters are upregulated by cAMP and cGMP, with AP2 and Sp1 binding sites identified as mediators.","method":"RACE-PCR, RT-PCR, promoter cloning, luciferase reporter assay, DNase I footprint analysis","journal":"International journal of impotence research","confidence":"High","confidence_rationale":"Tier 1 — multiple orthogonal methods including reporter assays and footprinting","pmids":["11896473"],"is_preprint":false},{"year":2001,"finding":"A 139-bp region containing the PDE5A1-specific first exon constitutes the core basal promoter; Sp1 and AP2 binding sites in flanking sequences mediate cAMP/cGMP-dependent transcriptional upregulation of PDE5A.","method":"Luciferase reporter assay, DNase I footprint analysis, deletion mapping","journal":"Biochemical and biophysical research communications","confidence":"High","confidence_rationale":"Tier 1 — multiple orthogonal methods in same study","pmids":["11162575"],"is_preprint":false},{"year":2000,"finding":"Three alternative first exons for PDE5A isoforms are arranged in order A1-A3-A2; the intron between the A3- and A2-specific exons has promoter activity bound by transcription factors AP-2 and Sp1, while the intron between A1- and A3-specific exons lacks promoter activity.","method":"RACE-PCR, promoter activity assays, DNase I footprint analysis","journal":"Biochemical and biophysical research communications","confidence":"High","confidence_rationale":"Tier 1 — footprinting and functional reporter assays","pmids":["10679249"],"is_preprint":false},{"year":2011,"finding":"In melanoma cells, oncogenic BRAF acting through MEK and the transcription factor BRN2 transcriptionally downregulates PDE5A, causing increased cGMP, elevated cytosolic Ca2+, increased actomyosin contractility, and stimulation of cell invasion and lung colonization.","method":"Genetic epistasis (BRAF/MEK/BRN2 manipulation), siRNA knockdown, cGMP measurement, Ca2+ imaging, invasion assays, mouse colonization model","journal":"Cancer cell","confidence":"High","confidence_rationale":"Tier 2 — genetic epistasis chain established with multiple orthogonal methods, highly cited","pmids":["21215707"],"is_preprint":false},{"year":2010,"finding":"PDE5A inhibition (sildenafil) suppresses beta-adrenergic receptor-stimulated cardiac contractility through a cascade requiring beta3-adrenergic receptor stimulation, NOS-NO-cGMP synthesis, PKG activation, and PKG-dependent phosphorylation of troponin I at Ser23/Ser24; this modulation does not involve cGMP cross-talk with PDE2 or PDE3.","method":"Genetic knockout mice (beta3-AR KO), pharmacological inhibitors, video microscopy (sarcomere shortening), Fura-2 Ca2+ imaging, non-equilibrium isoelectric focusing gel electrophoresis for TnI phosphorylation","journal":"Basic research in cardiology","confidence":"High","confidence_rationale":"Tier 2 — epistasis with genetic KO mice, multiple orthogonal functional readouts","pmids":["20107996"],"is_preprint":false},{"year":2008,"finding":"PDE5 is expressed and enzymatically active in cardiac myocytes, localizes to z-bands in an eNOS-dependent manner (DsRed-PDE5 fusion protein is diffuse in eNOS-/- myocytes), and its inhibition or gene silencing (shRNA) suppresses phenylephrine-induced hypertrophy through a PKG-dependent mechanism.","method":"shRNA gene silencing (miRNA-155 cassette), DsRed-PDE5 fusion protein expression, immunofluorescence, enzyme activity assay, video microscopy, genetic knockout (eNOS-/-)","journal":"Cellular signalling","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal methods (KD, OE, localization, activity assay, KO) in single study","pmids":["18790048"],"is_preprint":false},{"year":2011,"finding":"PDE5A localizes to caveolae in vascular endothelial cells; PDE5A inhibitors increase NOS3 activity, while adenoviral PDE5A overexpression decreases NOS3 activity and PKG1 activity. PKG1 directly regulates NOS3 phosphorylation at S1179, establishing a cGMP-dependent feedback loop between endothelial PDE5A and NOS3.","method":"Subcellular fractionation to caveolin-rich lipid rafts, adenoviral overexpression in vitro and in vivo, siRNA knockdown of PKG1, NOS3 activity assays, vasodilation measurements","journal":"Cardiovascular research","confidence":"High","confidence_rationale":"Tier 2 — reciprocal gain/loss-of-function, multiple orthogonal methods, human/mouse/bovine models","pmids":["21421555"],"is_preprint":false},{"year":2008,"finding":"The anti-hypertrophic efficacy of PDE5A inhibition is magnitude-dependent on pressure-overload stress: sildenafil is ineffective against modest hypertrophy (low stress) but effective at higher stress levels where pathologic signaling (calcineurin, ERK-MAPK) is activated and suppressible by cGK-1, while modest hypertrophy is associated with enhanced GSK3beta/Akt phosphorylation that sildenafil further promotes.","method":"Transverse aortic constriction (TAC) mouse model at two severity levels, oral sildenafil, LV mass measurement, signaling kinase activity assays (calcineurin, ERK, GSK3beta, Akt), cGK-1 activity assay","journal":"Journal of molecular and cellular cardiology","confidence":"High","confidence_rationale":"Tier 2 — epistasis via dose-response stress model, multiple signaling pathway readouts","pmids":["19159628"],"is_preprint":false},{"year":2014,"finding":"Ser102 and Ser104 in PDE5A regulate its conformational flexibility and enzymatic activity; the double Ser102Ala/Ser104Ala mutant shows approximately two-fold higher cGMP hydrolysis activity than wild-type and migrates as a single band on native gels (vs. doublet for WT), indicating these serines influence phosphorylation status and allosteric regulation.","method":"Site-directed mutagenesis, in vitro cGMP hydrolysis assay with [3H]cGMP, native PAGE, GFP fusion protein expression in neuroblastoma cells, immunofluorescence","journal":"PloS one","confidence":"Medium","confidence_rationale":"Tier 1 — in vitro activity assay with mutagenesis, single lab","pmids":["25247292"],"is_preprint":false},{"year":2018,"finding":"miR-19a/b-3p directly targets PDE5A mRNA at its 3'UTR to suppress PDE5A expression; reduced miR-19a/b-3p levels in pressure-overload hypertrophic hearts lead to increased PDE5A and cardiac remodeling, while miR-19a/b-3p transgenic mice are protected from angiotensin II-induced cardiac hypertrophy.","method":"Luciferase reporter assay, miRNA transfection, RT-PCR, western blot, transgenic mouse model, echocardiography, pressure-volume analysis","journal":"Journal of hypertension","confidence":"High","confidence_rationale":"Tier 2 — direct 3'UTR targeting confirmed by luciferase assay, validated in transgenic mouse model","pmids":["29664809"],"is_preprint":false},{"year":2024,"finding":"The deubiquitinase OTUD1 binds directly to the GAF1 and PDEase domains of PDE5A (by Co-IP and LC-MS/MS) and removes K48-linked ubiquitin chains from PDE5A through its catalytic cysteine at position 320, thereby preventing PDE5A proteasomal degradation. Stabilized PDE5A inactivates the cGMP-PKG-SERCA2a signaling axis, dysregulating calcium handling in cardiomyocytes and promoting heart failure.","method":"LC-MS/MS, Co-immunoprecipitation, domain mapping, ubiquitination assays, NRVM knockdown/overexpression, calcium handling measurements","journal":"Biochimica et biophysica acta. Molecular basis of disease","confidence":"High","confidence_rationale":"Tier 1-2 — Co-IP with domain mapping, LC-MS/MS, enzymatic mechanism (deubiquitination) identified with mutant","pmids":["38185350"],"is_preprint":false},{"year":2022,"finding":"PDE5A deficiency in platelets elevates intracellular cGMP and VASP phosphorylation, and impairs platelet aggregation, ATP release, P-selectin expression, integrin alphaIIbbeta3 activation, spreading, clot retraction, phosphatidylserine exposure, calcium mobilization, and ROS production, resulting in delayed arterial and venous thrombus formation in vivo.","method":"PDE5A knockout mice, platelet aggregation assays, flow cytometry, calcium mobilization (Fluo-4 AM), western blot (VASP, ERK, AKT phosphorylation), FeCl3-induced thrombosis model, microfluidic perfusion assay","journal":"Thrombosis and haemostasis","confidence":"High","confidence_rationale":"Tier 2 — genetic KO with multiple orthogonal platelet function readouts in vitro and in vivo","pmids":["36252813"],"is_preprint":false},{"year":2017,"finding":"Murine PDE5A isoforms A1, A2, and A3 were produced in Kluyveromyces lactis with Km, Vmax, and sildenafil inhibition kinetic constants similar to native murine enzymes, confirming that the regulatory and catalytic domains of PDE5A function properly in heterologous eukaryotic expression.","method":"Heterologous protein expression, in vitro enzymatic kinetic assay (Km, Vmax), inhibitor (sildenafil) IC50 determination","journal":"Microbial cell factories","confidence":"Medium","confidence_rationale":"Tier 1 — in vitro enzymatic characterization with kinetics, single lab","pmids":["28938916"],"is_preprint":false},{"year":2019,"finding":"PDE5A overexpression in C2C12 myotubes suppresses proteasome activity, leading to ER stress and subsequent insulin resistance (reduced Akt phosphorylation and glucose uptake); PDE5A knockdown has the opposite effect. PDE5 inhibition by icariin restores proteasome activity, reduces ER stress, and rescues insulin signaling.","method":"Adenoviral overexpression/knockdown, western blot (Akt phosphorylation), 2-DG glucose uptake assay, proteasome activity assay, ER stress markers","journal":"International journal of endocrinology","confidence":"Medium","confidence_rationale":"Tier 2 — reciprocal gain/loss-of-function with multiple readouts, single lab","pmids":["30774657"],"is_preprint":false},{"year":2019,"finding":"In zebrafish, PDE5ab (ortholog of mammalian PDE5A) is expressed in oocytes and becomes phosphorylated during human chorionic gonadotropin-induced oocyte maturation; PDE5A inhibitors (sildenafil, tadalafil) stimulate oocyte maturation through a PKG-dependent and gap junction-dependent mechanism.","method":"In situ hybridization, western blot with phospho-specific antibody, pharmacological inhibition (sildenafil, tadalafil, KT5823 PKG inhibitor, gap junction blockers), oocyte maturation assay","journal":"General and comparative endocrinology","confidence":"Medium","confidence_rationale":"Tier 2 — functional pharmacological dissection in zebrafish oocyte model, consistent with mammalian PDE5A biology","pmids":["31654676"],"is_preprint":false},{"year":2025,"finding":"Pde5a deficiency in mice activates the cAMP-PKA signaling pathway in adipose tissue, promotes brown adipose tissue activation and white adipose tissue browning, reduces hepatic lipid accumulation, and confers resistance to diet-induced obesity with improved glucose metabolism; this indicates PDE5A regulates energy homeostasis through convergence of cGMP and cAMP signaling.","method":"Pde5a knockout mouse models, high-fat diet challenge, histological analysis, metabolic phenotyping, thermogenesis measurements, cAMP/cGMP measurement, PKA activity assay","journal":"Molecular metabolism","confidence":"High","confidence_rationale":"Tier 2 — genetic KO with multiple metabolic phenotyping methods, mechanism via cAMP-PKA pathway identified","pmids":["40912399"],"is_preprint":false},{"year":2024,"finding":"PDE5A overexpression in striatal neurons decreases cGMP levels, reduces dendritic complexity, increases apoptosis, and enhances neuronal excitability; these effects are rescued by the PDE5 inhibitor tadalafil. In vivo stereotaxic overexpression in mouse striatum upregulates neuroinflammation gene expression and induces bipolar disorder-like behaviors.","method":"Overexpression in primary cultured striatal neurons, stereotaxic viral injection in mouse striatum, cGMP measurement, morphological analysis, electrophysiology, behavioral testing, snRNA-seq validation in human brain","journal":"Translational psychiatry","confidence":"High","confidence_rationale":"Tier 2 — gain-of-function with multiple orthogonal cellular and in vivo readouts plus human snRNA-seq validation","pmids":["39695100"],"is_preprint":false},{"year":2025,"finding":"The transcription factor RUNX1 acts as a transcriptional repressor of PDE5A in vascular smooth muscle cells; exercise reduces RUNX1 expression, upregulates PDE5A, maintains VSMC contractile phenotype, and attenuates aortic dissection. VSMC-specific PDE5A overexpression recapitulates these protective effects, while PDE5A inhibition abolishes exercise benefit.","method":"RNA sequencing, gain/loss-of-function experiments (VSMC-specific overexpression), VSMC phenotype marker analysis, beta-aminopropionitrile AD mouse model, treadmill exercise intervention, chromatin immunoprecipitation (implied by transcriptional repressor identification)","journal":"Arteriosclerosis, thrombosis, and vascular biology","confidence":"Medium","confidence_rationale":"Tier 2 — genetic gain/loss-of-function with clear in vivo phenotype, single lab","pmids":["41853865"],"is_preprint":false},{"year":2025,"finding":"In Pde5a-deficient mice, loss of PDE5A results in unbalanced cAMP/cGMP ratio and metabolic reprogramming toward mixed oxidative-glycolytic metabolism under pressure overload (TAC), demonstrating that PDE5A modulates cyclic nucleotide homeostasis that controls cardiac metabolic state; pharmacological sildenafil prevents moderate but not severe TAC-induced hypertrophy in wild-type mice.","method":"Pde5a knockout mice, transverse aortic constriction, echocardiography, cAMP/cGMP measurement, lactate dehydrogenase assays, molecular marker expression, sildenafil treatment","journal":"Life science alliance","confidence":"Medium","confidence_rationale":"Tier 2 — genetic KO with mechanistic metabolic readouts, single lab","pmids":["40659490"],"is_preprint":false},{"year":2025,"finding":"PDE5A+ cancer-associated fibroblasts promote gastric cancer immune suppression by activating the PI3K/AKT/mTOR signaling pathway and releasing CXCL12, which engages CXCR4 on CD8+ TEX+ LAG3 T cells to recruit them and facilitate immunosuppressive tumor microenvironment; combined LAG3 blockade and PDE5A inhibitor (vardenafil) enhanced immunotherapy responses in mouse models.","method":"Single-cell RNA sequencing, spatial transcriptomics, in vitro/in vivo mechanistic studies, pathway inhibition, combination therapy in mouse models","journal":"Gut","confidence":"Medium","confidence_rationale":"Tier 2 — scRNA-seq with in vitro/in vivo mechanistic validation, single lab","pmids":["41115748"],"is_preprint":false},{"year":2013,"finding":"Chronic vasodilation increases renal medullary PDE5A protein abundance through an AT1 receptor (angiotensin type 1)-dependent mechanism, as blockade of AT1 receptors (losartan) or ACE (enalapril) prevents the PDE5A upregulation, while mineralocorticoid receptor blockade (spironolactone) does not.","method":"Pharmacological intervention in rats (nifedipine, losartan, enalapril, spironolactone), western blot for renal medullary PDE5A protein","journal":"American journal of physiology. Regulatory, integrative and comparative physiology","confidence":"Medium","confidence_rationale":"Tier 2 — multiple pharmacological interventions defining upstream regulatory pathway, single lab","pmids":["24068049"],"is_preprint":false},{"year":2020,"finding":"Burn injury disrupts the PDE5A-cGMP-PKG signaling pathway in cardiac tissue, causing mitochondrial morphological damage, reduced mitochondrial number/area, decreased mitochondrial complex I/III/IV activity (but not complex II), reduced state 3 oxygen consumption, and decreased ATP and MnSOD activity. Sildenafil (PDE5A inhibitor) preserves mitochondrial structure and respiratory chain efficiency.","method":"Rat burn model, transmission electron microscopy, real-time qPCR (mitDNA genes), O2K-respirometry, electron transport chain activity assays, ATP measurement, sildenafil treatment","journal":"International journal of molecular sciences","confidence":"Medium","confidence_rationale":"Tier 2 — multiple orthogonal mitochondrial function assays with pharmacological rescue, single lab","pmids":["32231130"],"is_preprint":false}],"current_model":"PDE5A is a cGMP-specific 3',5'-cyclic nucleotide phosphodiesterase that hydrolyzes cGMP to GMP; it is regulated transcriptionally (by BRAF-MEK-BRN2, RUNX1, miR-19a/b-3p, miR-30d, and cAMP/cGMP via Sp1/AP2 promoter elements), post-translationally (by OTUD1-mediated deubiquitination stabilizing it from proteasomal degradation, and by Ser102/Ser104 phosphorylation influencing its activity), and spatially (localizing to endothelial caveolae in an eNOS-dependent manner and to z-bands in cardiomyocytes); through modulation of intracellular cGMP levels it controls downstream PKG activation to regulate cardiac contractility (via troponin I phosphorylation), vascular smooth muscle tone, platelet activation and thrombus formation, melanoma cell invasion via Ca2+ signaling, adipose tissue thermogenesis via cAMP-PKA crosstalk, and neuronal excitability in striatal neurons."},"narrative":{"teleology":[{"year":1998,"claim":"Establishing the molecular identity and enzymatic specificity of PDE5A resolved that human PDE5A1 encodes an 875-amino-acid cGMP-specific phosphodiesterase inhibitable by zaprinast and DMPPO, and that the gene maps to 4q26 with 21 exons sharing structural homology with PDE6B.","evidence":"Heterologous expression in yeast with enzymatic assay and pharmacological inhibition; genomic sequencing and FISH mapping","pmids":["9714779","9716380"],"confidence":"High","gaps":["No crystal structure of full-length human PDE5A determined in these studies","Substrate kinetics for different isoforms not compared"]},{"year":2002,"claim":"Defining the promoter architecture and isoform regulation revealed that three PDE5A isoforms arise from two alternative promoters with Sp1/AP-2 elements mediating cAMP/cGMP-dependent transcriptional upregulation, establishing a cyclic nucleotide feedback loop at the transcriptional level.","evidence":"RACE-PCR, luciferase reporter assays, DNase I footprinting, and deletion mapping across multiple studies","pmids":["10679249","11162575","11896473"],"confidence":"High","gaps":["Identity of kinases or phosphatases mediating the cAMP/cGMP signal to Sp1/AP-2 not defined","Relative physiological contribution of each promoter in specific tissues unknown"]},{"year":2008,"claim":"Demonstrating that PDE5A is expressed and active in cardiomyocytes with eNOS-dependent z-band localization, and that its inhibition suppresses hypertrophy via PKG, established PDE5A as a spatially compartmentalized cardiac signaling node rather than solely a vascular smooth muscle enzyme.","evidence":"shRNA knockdown, DsRed-PDE5 fusion imaging, eNOS knockout mice, enzyme activity assay, video microscopy of sarcomere shortening","pmids":["18790048","19159628"],"confidence":"High","gaps":["Mechanism anchoring PDE5A to z-bands not identified","Whether cardiac PDE5A isoform expression differs from vascular tissues not resolved"]},{"year":2010,"claim":"Mapping the full signaling cascade from PDE5A inhibition through β3-adrenergic receptor/NOS/cGMP/PKG to troponin I Ser23/24 phosphorylation defined the complete molecular pathway by which PDE5A controls cardiac contractility, ruling out PDE2/PDE3 cross-talk.","evidence":"β3-AR knockout mice, pharmacological inhibitors, sarcomere shortening video microscopy, Fura-2 Ca²⁺ imaging, TnI phosphorylation gel electrophoresis","pmids":["20107996"],"confidence":"High","gaps":["Whether this pathway operates identically in human cardiomyocytes not demonstrated","Role of PDE5A in diastolic function not addressed"]},{"year":2011,"claim":"Two discoveries expanded PDE5A's regulatory context: in endothelial cells PDE5A localizes to caveolae and engages a PKG1-NOS3 feedback loop, while in melanoma BRAF-MEK-BRN2 transcriptionally represses PDE5A to elevate cGMP-Ca²⁺ signaling and drive invasion.","evidence":"Caveolar fractionation with adenoviral overexpression/siRNA and vasodilation assays; genetic epistasis with BRAF/MEK/BRN2, cGMP/Ca²⁺ imaging, mouse colonization model","pmids":["21421555","21215707"],"confidence":"High","gaps":["Direct BRN2 binding site on PDE5A promoter not mapped","Whether caveolar localization requires direct caveolin binding not established"]},{"year":2014,"claim":"Mutagenesis of Ser102/Ser104 showed these residues control PDE5A conformational flexibility and catalytic activity, with the double alanine mutant exhibiting ~2-fold higher cGMP hydrolysis, revealing an allosteric regulatory site distinct from the catalytic pocket.","evidence":"Site-directed mutagenesis, [³H]cGMP hydrolysis assay, native PAGE","pmids":["25247292"],"confidence":"Medium","gaps":["Identity of the kinase(s) phosphorylating Ser102/Ser104 in vivo not determined","Structural basis of conformational change not resolved","Single lab, no independent replication"]},{"year":2018,"claim":"Identification of miR-19a/b-3p as a direct post-transcriptional repressor of PDE5A via its 3'UTR, with transgenic mice protected from cardiac hypertrophy, established microRNA control as a disease-relevant layer of PDE5A regulation.","evidence":"Luciferase 3'UTR reporter assay, miRNA transgenic mice, echocardiography, pressure-volume analysis","pmids":["29664809"],"confidence":"High","gaps":["Whether other miRNAs cooperate to regulate PDE5A in the heart not explored","Relative contribution of miR-19a vs miR-19b not distinguished"]},{"year":2022,"claim":"PDE5A knockout platelets revealed that PDE5A is essential for normal platelet activation, demonstrating that loss of PDE5A elevates cGMP-VASP signaling and broadly impairs aggregation, secretion, integrin activation, and thrombus formation in vivo.","evidence":"PDE5A knockout mice, platelet aggregation, flow cytometry, Fluo-4 AM Ca²⁺ mobilization, FeCl₃ thrombosis model, microfluidic perfusion","pmids":["36252813"],"confidence":"High","gaps":["Whether PDE5A-deficient platelets have altered bleeding times not reported","Contribution of individual PDE5A isoforms in platelets unknown"]},{"year":2024,"claim":"Discovery that OTUD1 deubiquitinates PDE5A by removing K48-linked ubiquitin chains through Cys320, preventing proteasomal degradation and thereby inactivating cGMP-PKG-SERCA2a signaling, identified a direct post-translational mechanism controlling PDE5A protein stability in cardiomyocytes and heart failure.","evidence":"LC-MS/MS, Co-IP with domain mapping (GAF1 and PDEase domains), ubiquitination assays with catalytic-dead mutant, NRVM knockdown/overexpression, calcium handling measurements","pmids":["38185350"],"confidence":"High","gaps":["E3 ubiquitin ligase targeting PDE5A for degradation not identified","Whether OTUD1-PDE5A interaction is regulated by upstream signals unknown"]},{"year":2025,"claim":"Multiple 2025 studies expanded PDE5A's systemic roles: adipose-specific Pde5a deficiency activated cAMP-PKA thermogenesis conferring obesity resistance; striatal PDE5A overexpression reduced dendritic complexity and increased neuronal excitability; RUNX1 was identified as a transcriptional repressor of PDE5A in VSMCs mediating exercise-protective effects; and Pde5a loss altered cardiac metabolic programming under pressure overload.","evidence":"Pde5a KO mice with metabolic phenotyping and cAMP/PKA assays; stereotaxic viral overexpression with electrophysiology and behavioral testing; VSMC-specific gain/loss-of-function in aortic dissection models; KO mice with TAC and metabolic readouts","pmids":["40912399","39695100","41853865","40659490"],"confidence":"High","gaps":["Whether cGMP-to-cAMP crosstalk in adipose tissue involves specific PDE isoform interactions not defined","Mechanism linking PDE5A to neuroinflammation gene expression in striatum not resolved","Direct RUNX1 binding to PDE5A promoter requires ChIP-seq confirmation"]},{"year":null,"claim":"Key unresolved questions include the identity of the E3 ubiquitin ligase that targets PDE5A for degradation, the structural basis of Ser102/104-dependent allosteric regulation, the mechanism anchoring PDE5A to z-bands, and how PDE5A coordinates cGMP and cAMP compartmentalization across different cell types.","evidence":"","pmids":[],"confidence":"Low","gaps":["No full-length human PDE5A structure with regulatory domains resolved","E3 ligase for PDE5A unknown","Mechanism of z-band and caveolar targeting undefined"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0016787","term_label":"hydrolase activity","supporting_discovery_ids":[0,10,14]},{"term_id":"GO:0140657","term_label":"ATP-dependent activity","supporting_discovery_ids":[0]}],"localization":[{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[8]},{"term_id":"GO:0005856","term_label":"cytoskeleton","supporting_discovery_ids":[7]},{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[7,8]}],"pathway":[{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[6,7,8,9,13,17,18]},{"term_id":"R-HSA-109582","term_label":"Hemostasis","supporting_discovery_ids":[13]},{"term_id":"R-HSA-1430728","term_label":"Metabolism","supporting_discovery_ids":[17,20]},{"term_id":"R-HSA-392499","term_label":"Metabolism of proteins","supporting_discovery_ids":[12]}],"complexes":[],"partners":["OTUD1","NOS3","PKG1","BRN2","RUNX1"],"other_free_text":[]},"mechanistic_narrative":"PDE5A is a cGMP-binding, cGMP-specific 3',5'-cyclic nucleotide phosphodiesterase that hydrolyzes cGMP to GMP, thereby controlling intracellular cGMP levels and downstream PKG signaling across diverse tissues including vascular smooth muscle, cardiomyocytes, platelets, adipose tissue, and neurons [PMID:9714779, PMID:20107996, PMID:36252813, PMID:40912399, PMID:39695100]. Three isoforms (PDE5A1, PDE5A2, PDE5A3) are generated from alternative promoters containing Sp1 and AP-2 elements that mediate cAMP/cGMP-dependent transcriptional feedback, while additional transcriptional regulation occurs through BRAF-MEK-BRN2 repression in melanoma and RUNX1 repression in vascular smooth muscle, and post-transcriptional control involves miR-19a/b-3p targeting of the 3'UTR [PMID:11896473, PMID:21215707, PMID:41853865, PMID:29664809]. Protein stability is regulated by OTUD1-mediated removal of K48-linked ubiquitin chains that protect PDE5A from proteasomal degradation, and phosphorylation at Ser102/Ser104 modulates conformational flexibility and catalytic activity [PMID:38185350, PMID:25247292]. In cardiomyocytes PDE5A localizes to z-bands in an eNOS-dependent manner and modulates contractility via PKG-dependent troponin I phosphorylation, while in platelets PDE5A loss elevates cGMP-VASP signaling to impair aggregation and thrombus formation, and in adipose tissue PDE5A deficiency activates cAMP-PKA–driven thermogenesis conferring resistance to diet-induced obesity [PMID:18790048, PMID:20107996, PMID:36252813, PMID:40912399]."},"prefetch_data":{"uniprot":{"accession":"O76074","full_name":"cGMP-specific 3',5'-cyclic phosphodiesterase","aliases":["cGMP-binding cGMP-specific phosphodiesterase","CGB-PDE"],"length_aa":875,"mass_kda":100.0,"function":"Plays a role in signal transduction by regulating the intracellular concentration of cyclic nucleotides. This phosphodiesterase catalyzes the specific hydrolysis of cGMP to 5'-GMP (PubMed:15489334, PubMed:9714779). Specifically regulates nitric-oxide-generated cGMP (PubMed:15489334)","subcellular_location":"","url":"https://www.uniprot.org/uniprotkb/O76074/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/PDE5A","classification":"Not Classified","n_dependent_lines":0,"n_total_lines":1208,"dependency_fraction":0.0},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/PDE5A","total_profiled":1310},"omim":[{"mim_id":"603310","title":"PHOSPHODIESTERASE 5A; PDE5A","url":"https://www.omim.org/entry/603310"},{"mim_id":"602973","title":"PHOSPHODIESTERASE 9A; PDE9A","url":"https://www.omim.org/entry/602973"},{"mim_id":"600716","title":"PROTEIN TYROSINE PHOSPHATASE, NONRECEPTOR-TYPE, 22; PTPN22","url":"https://www.omim.org/entry/600716"},{"mim_id":"178400","title":"PULMONARY EDEMA OF MOUNTAINEERS, SUSCEPTIBILITY TO","url":"https://www.omim.org/entry/178400"},{"mim_id":"176894","title":"PROTEIN KINASE, cGMP-DEPENDENT, REGULATORY, TYPE I; PRKG1","url":"https://www.omim.org/entry/176894"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Approved","locations":[{"location":"Cytosol","reliability":"Approved"},{"location":"Basal body","reliability":"Additional"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/PDE5A"},"hgnc":{"alias_symbol":[],"prev_symbol":[]},"alphafold":{"accession":"O76074","domains":[{"cath_id":"3.30.450.40","chopping":"147-326","consensus_level":"high","plddt":85.6165,"start":147,"end":326},{"cath_id":"3.30.450.40","chopping":"344-392_407-433_448-512","consensus_level":"high","plddt":87.6772,"start":344,"end":512},{"cath_id":"1.10.1300.10","chopping":"532-866","consensus_level":"medium","plddt":94.6164,"start":532,"end":866}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/O76074","model_url":"https://alphafold.ebi.ac.uk/files/AF-O76074-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-O76074-F1-predicted_aligned_error_v6.png","plddt_mean":82.0},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=PDE5A","jax_strain_url":"https://www.jax.org/strain/search?query=PDE5A"},"sequence":{"accession":"O76074","fasta_url":"https://rest.uniprot.org/uniprotkb/O76074.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/O76074/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/O76074"}},"corpus_meta":[{"pmid":"21215707","id":"PMC_21215707","title":"Oncogenic BRAF induces melanoma cell invasion by downregulating the cGMP-specific phosphodiesterase PDE5A.","date":"2011","source":"Cancer cell","url":"https://pubmed.ncbi.nlm.nih.gov/21215707","citation_count":184,"is_preprint":false},{"pmid":"9714779","id":"PMC_9714779","title":"Isolation and characterization of cDNAs encoding PDE5A, a human cGMP-binding, cGMP-specific 3',5'-cyclic nucleotide phosphodiesterase.","date":"1998","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/9714779","citation_count":174,"is_preprint":false},{"pmid":"17965319","id":"PMC_17965319","title":"PDE5A inhibition attenuates bleomycin-induced pulmonary fibrosis and pulmonary hypertension through inhibition of ROS generation and RhoA/Rho kinase activation.","date":"2007","source":"American journal of physiology. Lung cellular and molecular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/17965319","citation_count":128,"is_preprint":false},{"pmid":"9716380","id":"PMC_9716380","title":"Expression, structure and chromosomal localization of the human cGMP-binding cGMP-specific phosphodiesterase PDE5A gene.","date":"1998","source":"European journal of biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/9716380","citation_count":100,"is_preprint":false},{"pmid":"11896473","id":"PMC_11896473","title":"Human PDE5A gene encodes three PDE5 isoforms from two alternate promoters.","date":"2002","source":"International journal of impotence research","url":"https://pubmed.ncbi.nlm.nih.gov/11896473","citation_count":88,"is_preprint":false},{"pmid":"20107996","id":"PMC_20107996","title":"PDE5A suppression of acute beta-adrenergic activation requires modulation of myocyte beta-3 signaling coupled to PKG-mediated troponin I phosphorylation.","date":"2010","source":"Basic research in cardiology","url":"https://pubmed.ncbi.nlm.nih.gov/20107996","citation_count":87,"is_preprint":false},{"pmid":"18790048","id":"PMC_18790048","title":"Expression, activity, and pro-hypertrophic effects of PDE5A in cardiac myocytes.","date":"2008","source":"Cellular signalling","url":"https://pubmed.ncbi.nlm.nih.gov/18790048","citation_count":78,"is_preprint":false},{"pmid":"35026404","id":"PMC_35026404","title":"Main active components of Si-Miao-Yong-An decoction (SMYAD) attenuate autophagy and apoptosis via the PDE5A-AKT and TLR4-NOX4 pathways in isoproterenol (ISO)-induced heart failure models.","date":"2022","source":"Pharmacological research","url":"https://pubmed.ncbi.nlm.nih.gov/35026404","citation_count":73,"is_preprint":false},{"pmid":"23117837","id":"PMC_23117837","title":"Selective PDE5A inhibition with sildenafil rescues left ventricular dysfunction, inflammatory immune response and cardiac remodeling in angiotensin II-induced heart failure in vivo.","date":"2012","source":"Basic research in cardiology","url":"https://pubmed.ncbi.nlm.nih.gov/23117837","citation_count":63,"is_preprint":false},{"pmid":"11162575","id":"PMC_11162575","title":"Identification and regulation of human PDE5A gene promoter.","date":"2001","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/11162575","citation_count":57,"is_preprint":false},{"pmid":"19159628","id":"PMC_19159628","title":"Pressure-overload magnitude-dependence of the anti-hypertrophic efficacy of PDE5A inhibition.","date":"2008","source":"Journal of molecular and cellular cardiology","url":"https://pubmed.ncbi.nlm.nih.gov/19159628","citation_count":45,"is_preprint":false},{"pmid":"21421555","id":"PMC_21421555","title":"Phosphodiesterase-5A (PDE5A) is localized to the endothelial caveolae and modulates NOS3 activity.","date":"2011","source":"Cardiovascular research","url":"https://pubmed.ncbi.nlm.nih.gov/21421555","citation_count":35,"is_preprint":false},{"pmid":"21987443","id":"PMC_21987443","title":"t(4;8)(q27;q24) in Hodgkin lymphoma cells targets phosphodiesterase PDE5A and homeobox gene ZHX2.","date":"2011","source":"Genes, chromosomes & cancer","url":"https://pubmed.ncbi.nlm.nih.gov/21987443","citation_count":29,"is_preprint":false},{"pmid":"29664809","id":"PMC_29664809","title":"MicroRNA-19a/b-3p protect the heart from hypertension-induced pathological cardiac hypertrophy through PDE5A.","date":"2018","source":"Journal of hypertension","url":"https://pubmed.ncbi.nlm.nih.gov/29664809","citation_count":28,"is_preprint":false},{"pmid":"32231130","id":"PMC_32231130","title":"Burn-Induced Cardiac Mitochondrial Dysfunction via Interruption of the PDE5A-cGMP-PKG Pathway.","date":"2020","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/32231130","citation_count":24,"is_preprint":false},{"pmid":"10679249","id":"PMC_10679249","title":"Identification of three alternative first exons and an intronic promoter of human PDE5A gene.","date":"2000","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/10679249","citation_count":24,"is_preprint":false},{"pmid":"26136059","id":"PMC_26136059","title":"Semi-synthetic derivatives of natural isoflavones from Maclura pomifera as a novel class of PDE-5A inhibitors.","date":"2015","source":"Fitoterapia","url":"https://pubmed.ncbi.nlm.nih.gov/26136059","citation_count":17,"is_preprint":false},{"pmid":"27676442","id":"PMC_27676442","title":"Reversal of neurobehavioral social deficits in dystrophic mice using inhibitors of phosphodiesterases PDE5A and PDE9A.","date":"2016","source":"Translational psychiatry","url":"https://pubmed.ncbi.nlm.nih.gov/27676442","citation_count":16,"is_preprint":false},{"pmid":"31053768","id":"PMC_31053768","title":"Effect of a phosphodiesterase-5A (PDE5A) gene polymorphism on response to sildenafil therapy in canine pulmonary hypertension.","date":"2019","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/31053768","citation_count":15,"is_preprint":false},{"pmid":"38185350","id":"PMC_38185350","title":"OTUD1 promotes isoprenaline- and myocardial infarction-induced heart failure by targeting PDE5A in cardiomyocytes.","date":"2024","source":"Biochimica et biophysica acta. Molecular basis of disease","url":"https://pubmed.ncbi.nlm.nih.gov/38185350","citation_count":15,"is_preprint":false},{"pmid":"33687636","id":"PMC_33687636","title":"LncRNA HOXA-AS3 Promotes the Progression of Pulmonary Arterial Hypertension through Mediation of miR-675-3p/PDE5A Axis.","date":"2021","source":"Biochemical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/33687636","citation_count":15,"is_preprint":false},{"pmid":"30774657","id":"PMC_30774657","title":"PDE5A Suppresses Proteasome Activity Leading to Insulin Resistance in C2C12 Myotubes.","date":"2019","source":"International journal of endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/30774657","citation_count":13,"is_preprint":false},{"pmid":"36587222","id":"PMC_36587222","title":"Isolation, bioassay and 3D-QSAR analysis of 8-isopentenyl flavonoids from Epimedium sagittatum maxim. as PDE5A inhibitors.","date":"2022","source":"Chinese medicine","url":"https://pubmed.ncbi.nlm.nih.gov/36587222","citation_count":12,"is_preprint":false},{"pmid":"35155444","id":"PMC_35155444","title":"Myostatin Mutation Promotes Glycolysis by Increasing Phosphorylation of Phosphofructokinase via Activation of PDE5A-cGMP-PKG in Cattle Heart.","date":"2022","source":"Frontiers in cell and developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/35155444","citation_count":11,"is_preprint":false},{"pmid":"24341639","id":"PMC_24341639","title":"Identification of PDE5A:E90K: a polymorphism in the canine phosphodiesterase 5A gene affecting basal cGMP concentrations of healthy dogs.","date":"2013","source":"Journal of veterinary internal medicine","url":"https://pubmed.ncbi.nlm.nih.gov/24341639","citation_count":11,"is_preprint":false},{"pmid":"36252813","id":"PMC_36252813","title":"Impaired Platelet Function and Thrombus Formation in PDE5A-Deficient Mice.","date":"2022","source":"Thrombosis and haemostasis","url":"https://pubmed.ncbi.nlm.nih.gov/36252813","citation_count":9,"is_preprint":false},{"pmid":"27235284","id":"PMC_27235284","title":"PDE5A Polymorphisms Influence on Sildenafil Treatment Success.","date":"2016","source":"The journal of sexual medicine","url":"https://pubmed.ncbi.nlm.nih.gov/27235284","citation_count":9,"is_preprint":false},{"pmid":"37017666","id":"PMC_37017666","title":"IncRNA XIST Stimulates Papillary Thyroid Cancer Development through the miR-330-3p/PDE5A Axis.","date":"2023","source":"Critical reviews in eukaryotic gene expression","url":"https://pubmed.ncbi.nlm.nih.gov/37017666","citation_count":8,"is_preprint":false},{"pmid":"31155983","id":"PMC_31155983","title":"Hydrogen sulfide-mediated endothelial function and the interaction with eNOS and PDE5A activity in human internal mammary arteries.","date":"2019","source":"The Journal of international medical research","url":"https://pubmed.ncbi.nlm.nih.gov/31155983","citation_count":7,"is_preprint":false},{"pmid":"20563733","id":"PMC_20563733","title":"Phosphodiesterase-5 gene (PDE5A) polymorphisms are associated with progression of childhood IgA nephropathy.","date":"2010","source":"Pediatric nephrology (Berlin, Germany)","url":"https://pubmed.ncbi.nlm.nih.gov/20563733","citation_count":7,"is_preprint":false},{"pmid":"31654676","id":"PMC_31654676","title":"The role of PDE5a in oocyte maturation of zebrafish.","date":"2019","source":"General and comparative endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/31654676","citation_count":6,"is_preprint":false},{"pmid":"36730555","id":"PMC_36730555","title":"LncRNA ARAP1-AS1 targets miR-516b-5p/PDE5A axis to facilitate the progression of thyroid cancer.","date":"2022","source":"Anti-cancer drugs","url":"https://pubmed.ncbi.nlm.nih.gov/36730555","citation_count":6,"is_preprint":false},{"pmid":"28938916","id":"PMC_28938916","title":"Use of the KlADH3 promoter for the quantitative production of the murine PDE5A isoforms in the yeast Kluyveromyces lactis.","date":"2017","source":"Microbial cell factories","url":"https://pubmed.ncbi.nlm.nih.gov/28938916","citation_count":6,"is_preprint":false},{"pmid":"39206778","id":"PMC_39206778","title":"miR-30d Attenuates Pulmonary Arterial Hypertension via Targeting MTDH and PDE5A and Modulates the Beneficial Effect of Sildenafil.","date":"2024","source":"Advanced science (Weinheim, Baden-Wurttemberg, Germany)","url":"https://pubmed.ncbi.nlm.nih.gov/39206778","citation_count":5,"is_preprint":false},{"pmid":"36217175","id":"PMC_36217175","title":"Multiomic analysis of papillary thyroid cancers identifies BAIAP2L1-BRAF fusion and requirement of TRIM25, PDE5A and PKCδ for tumorigenesis.","date":"2022","source":"Molecular cancer","url":"https://pubmed.ncbi.nlm.nih.gov/36217175","citation_count":5,"is_preprint":false},{"pmid":"38135092","id":"PMC_38135092","title":"Ent-labdane-type diterpene glycosides obtained from Rubus chingii Hu and their inhibitory effects on PDE5A activity.","date":"2023","source":"Fitoterapia","url":"https://pubmed.ncbi.nlm.nih.gov/38135092","citation_count":4,"is_preprint":false},{"pmid":"25247292","id":"PMC_25247292","title":"Role of Ser102 and Ser104 as regulators of cGMP hydrolysis by PDE5A.","date":"2014","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/25247292","citation_count":4,"is_preprint":false},{"pmid":"39543318","id":"PMC_39543318","title":"Downregulation of miR-214 promotes dilated Cardiomyopathy Progression through PDE5A-Mediated cGMP regulation.","date":"2024","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/39543318","citation_count":4,"is_preprint":false},{"pmid":"31137981","id":"PMC_31137981","title":"Discovery of two novel hetero-tricyclic lead scaffolds as PDE5A inhibitor: virtual screening, molecular docking and pharmacophore modeling approach.","date":"2019","source":"Natural product research","url":"https://pubmed.ncbi.nlm.nih.gov/31137981","citation_count":4,"is_preprint":false},{"pmid":"40300852","id":"PMC_40300852","title":"Vascular remodeling in arteriovenous fistula treated with PDE5A inhibitors.","date":"2025","source":"Physiological reports","url":"https://pubmed.ncbi.nlm.nih.gov/40300852","citation_count":3,"is_preprint":false},{"pmid":"36860644","id":"PMC_36860644","title":"A label-free LC/MS-based enzymatic activity assay for the detection of PDE5A inhibitors.","date":"2023","source":"Frontiers in chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/36860644","citation_count":3,"is_preprint":false},{"pmid":"34768607","id":"PMC_34768607","title":"Sildenafil Citrate Downregulates PDE5A mRNA Expression in Women with Recurrent Pregnancy Loss without Altering Angiogenic Factors-A Preliminary Study.","date":"2021","source":"Journal of clinical medicine","url":"https://pubmed.ncbi.nlm.nih.gov/34768607","citation_count":3,"is_preprint":false},{"pmid":"24068049","id":"PMC_24068049","title":"Chronic vasodilation increases renal medullary PDE5A and α-ENaC through independent renin-angiotensin-aldosterone system pathways.","date":"2013","source":"American journal of physiology. Regulatory, integrative and comparative physiology","url":"https://pubmed.ncbi.nlm.nih.gov/24068049","citation_count":3,"is_preprint":false},{"pmid":"30747070","id":"PMC_30747070","title":"Novel Pyrazolo[4, 3-c]Quinolin-3-One Derivatives as PDE5A Inhibitors.","date":"2019","source":"Current topics in medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/30747070","citation_count":3,"is_preprint":false},{"pmid":"41115748","id":"PMC_41115748","title":"PDE5A+ cancer-associated fibroblasts enhance immune suppression in gastric cancer.","date":"2025","source":"Gut","url":"https://pubmed.ncbi.nlm.nih.gov/41115748","citation_count":2,"is_preprint":false},{"pmid":"40912399","id":"PMC_40912399","title":"Pde5a deficiency prevents diet-induced obesity via adipose cAMP-PKA activation enhancing fat browning.","date":"2025","source":"Molecular metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/40912399","citation_count":2,"is_preprint":false},{"pmid":"36442224","id":"PMC_36442224","title":"Co-expression of soluble guanylyl cyclase subunits and PDE5A shRNA to elevate cellular cGMP level: A potential gene therapy for myocardial cell death.","date":"2023","source":"Technology and health care : official journal of the European Society for Engineering and Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/36442224","citation_count":2,"is_preprint":false},{"pmid":"39774071","id":"PMC_39774071","title":"Icariin targets PDE5A to regulate viability, DNA synthesis and DNA damage of spermatogonial stem cells and improves reproductive capacity.","date":"2025","source":"Asian journal of andrology","url":"https://pubmed.ncbi.nlm.nih.gov/39774071","citation_count":2,"is_preprint":false},{"pmid":"34829647","id":"PMC_34829647","title":"Long-Term PDE-5A Inhibition Improves Myofilament Function in Left and Right Ventricular Cardiomyocytes through Partially Different Mechanisms in Diabetic Rat Hearts.","date":"2021","source":"Antioxidants (Basel, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/34829647","citation_count":2,"is_preprint":false},{"pmid":"38286403","id":"PMC_38286403","title":"Hsa_circ_0092355 Accelerates Papillary Thyroid Cancer Progression by Regulating the miR-543/PDE5A Pathway.","date":"2024","source":"Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme","url":"https://pubmed.ncbi.nlm.nih.gov/38286403","citation_count":1,"is_preprint":false},{"pmid":"38094047","id":"PMC_38094047","title":"Icariin has the potential to induce the differentiation of bone marrow mesenchymal stem cells into brown fat cells via PDE5A inhibition.","date":"2023","source":"Heliyon","url":"https://pubmed.ncbi.nlm.nih.gov/38094047","citation_count":1,"is_preprint":false},{"pmid":"30767749","id":"PMC_30767749","title":"Hetero-Tricyclic Lead Scaffold as Novel PDE5A Inhibitor for Antihypertensive Activity: In Silico Docking Studies.","date":"2019","source":"Current computer-aided drug design","url":"https://pubmed.ncbi.nlm.nih.gov/30767749","citation_count":1,"is_preprint":false},{"pmid":"40659490","id":"PMC_40659490","title":"The rewiring of cAMP/cGMP and LDH signalling drives cardiac hypertrophy in Pde5a  mice.","date":"2025","source":"Life science alliance","url":"https://pubmed.ncbi.nlm.nih.gov/40659490","citation_count":0,"is_preprint":false},{"pmid":"39695100","id":"PMC_39695100","title":"Exploring PDE5A upregulation in bipolar disorder: insights from single-nucleus RNA sequencing of human basal ganglia.","date":"2024","source":"Translational psychiatry","url":"https://pubmed.ncbi.nlm.nih.gov/39695100","citation_count":0,"is_preprint":false},{"pmid":"41853865","id":"PMC_41853865","title":"Exercise Attenuates Aortic Dissection Via PDE5A-Mediated Inhibition of Vascular Smooth Muscle Cell Phenotypic Switch.","date":"2026","source":"Arteriosclerosis, thrombosis, and vascular biology","url":"https://pubmed.ncbi.nlm.nih.gov/41853865","citation_count":0,"is_preprint":false},{"pmid":"41677948","id":"PMC_41677948","title":"Endothelial miR-7052 Safeguards Blood-Brain Barrier Integrity During Endotoxemia by Co-repressing ANGPT2 and PDE5A.","date":"2026","source":"Molecular neurobiology","url":"https://pubmed.ncbi.nlm.nih.gov/41677948","citation_count":0,"is_preprint":false},{"pmid":null,"id":"bio_10.1101_2025.02.05.636635","title":"<i>Pde5a</i> Deficiency Prevents Diet-Induced Obesity via Adipose cAMP-PKA Activation Enhancing Fat Browning","date":"2025-02-08","source":"bioRxiv","url":"https://doi.org/10.1101/2025.02.05.636635","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2025.03.24.645113","title":"β-aminopropionitrile-induced thoracic aortopathy is refractory to cilostazol and sildenafil in mice","date":"2025-03-27","source":"bioRxiv","url":"https://doi.org/10.1101/2025.03.24.645113","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2024.08.22.24312458","title":"Triangulating Evidence for Antihypertensive Drug Class Efficacy on Cardiovascular and Metabolic Outcomes Using Mendelian Randomisation and Colocalisation","date":"2024-08-23","source":"bioRxiv","url":"https://doi.org/10.1101/2024.08.22.24312458","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2024.06.18.599563","title":"RUNX1 Isoforms Regulate RUNX1 and Target-Genes Differentially in Platelets-Megakaryocytes: Association with Clinical Cardiovascular Events","date":"2024-06-21","source":"bioRxiv","url":"https://doi.org/10.1101/2024.06.18.599563","citation_count":0,"is_preprint":true}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":34393,"output_tokens":6001,"usd":0.096597},"stage2":{"model":"claude-opus-4-6","input_tokens":9560,"output_tokens":3241,"usd":0.193238},"total_usd":0.289835,"stage1_batch_id":"msgbatch_012ZiiCUBfB62NCTQd4Bk1Jo","stage2_batch_id":"msgbatch_01Xuqq9aUHoQouS7UVGZNStZ","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1998,\n      \"finding\": \"Human PDE5A1 encodes an 875-amino-acid cGMP-binding, cGMP-specific 3',5'-cyclic nucleotide phosphodiesterase that hydrolyzes cGMP; this activity is inhibited by selective PDE5 inhibitors zaprinast and DMPPO, as demonstrated by expression in yeast and enzymatic assay.\",\n      \"method\": \"Heterologous expression in yeast, in vitro enzymatic assay, pharmacological inhibition\",\n      \"journal\": \"Gene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — reconstituted enzymatic activity in yeast, inhibitor validation, replicated across labs\",\n      \"pmids\": [\"9714779\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"The human PDE5A gene contains 21 exons and maps to chromosome 4q26; its catalytic domain shows evolutionary relatedness to the rod photoreceptor phosphodiesterase beta-subunit (PDE6B) gene based on exon-intron organization comparison.\",\n      \"method\": \"Genomic library isolation, FISH chromosomal mapping, genomic structure analysis\",\n      \"journal\": \"European journal of biochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — direct genomic sequencing and FISH, multiple orthogonal methods\",\n      \"pmids\": [\"9716380\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"The human PDE5A gene encodes three isoforms (PDE5A1, PDE5A2, PDE5A3) from two alternative promoters; the upstream promoter drives all three isoforms while an intronic promoter drives only PDE5A2. Both promoters are upregulated by cAMP and cGMP, with AP2 and Sp1 binding sites identified as mediators.\",\n      \"method\": \"RACE-PCR, RT-PCR, promoter cloning, luciferase reporter assay, DNase I footprint analysis\",\n      \"journal\": \"International journal of impotence research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — multiple orthogonal methods including reporter assays and footprinting\",\n      \"pmids\": [\"11896473\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"A 139-bp region containing the PDE5A1-specific first exon constitutes the core basal promoter; Sp1 and AP2 binding sites in flanking sequences mediate cAMP/cGMP-dependent transcriptional upregulation of PDE5A.\",\n      \"method\": \"Luciferase reporter assay, DNase I footprint analysis, deletion mapping\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — multiple orthogonal methods in same study\",\n      \"pmids\": [\"11162575\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"Three alternative first exons for PDE5A isoforms are arranged in order A1-A3-A2; the intron between the A3- and A2-specific exons has promoter activity bound by transcription factors AP-2 and Sp1, while the intron between A1- and A3-specific exons lacks promoter activity.\",\n      \"method\": \"RACE-PCR, promoter activity assays, DNase I footprint analysis\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — footprinting and functional reporter assays\",\n      \"pmids\": [\"10679249\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"In melanoma cells, oncogenic BRAF acting through MEK and the transcription factor BRN2 transcriptionally downregulates PDE5A, causing increased cGMP, elevated cytosolic Ca2+, increased actomyosin contractility, and stimulation of cell invasion and lung colonization.\",\n      \"method\": \"Genetic epistasis (BRAF/MEK/BRN2 manipulation), siRNA knockdown, cGMP measurement, Ca2+ imaging, invasion assays, mouse colonization model\",\n      \"journal\": \"Cancer cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic epistasis chain established with multiple orthogonal methods, highly cited\",\n      \"pmids\": [\"21215707\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"PDE5A inhibition (sildenafil) suppresses beta-adrenergic receptor-stimulated cardiac contractility through a cascade requiring beta3-adrenergic receptor stimulation, NOS-NO-cGMP synthesis, PKG activation, and PKG-dependent phosphorylation of troponin I at Ser23/Ser24; this modulation does not involve cGMP cross-talk with PDE2 or PDE3.\",\n      \"method\": \"Genetic knockout mice (beta3-AR KO), pharmacological inhibitors, video microscopy (sarcomere shortening), Fura-2 Ca2+ imaging, non-equilibrium isoelectric focusing gel electrophoresis for TnI phosphorylation\",\n      \"journal\": \"Basic research in cardiology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — epistasis with genetic KO mice, multiple orthogonal functional readouts\",\n      \"pmids\": [\"20107996\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"PDE5 is expressed and enzymatically active in cardiac myocytes, localizes to z-bands in an eNOS-dependent manner (DsRed-PDE5 fusion protein is diffuse in eNOS-/- myocytes), and its inhibition or gene silencing (shRNA) suppresses phenylephrine-induced hypertrophy through a PKG-dependent mechanism.\",\n      \"method\": \"shRNA gene silencing (miRNA-155 cassette), DsRed-PDE5 fusion protein expression, immunofluorescence, enzyme activity assay, video microscopy, genetic knockout (eNOS-/-)\",\n      \"journal\": \"Cellular signalling\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods (KD, OE, localization, activity assay, KO) in single study\",\n      \"pmids\": [\"18790048\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"PDE5A localizes to caveolae in vascular endothelial cells; PDE5A inhibitors increase NOS3 activity, while adenoviral PDE5A overexpression decreases NOS3 activity and PKG1 activity. PKG1 directly regulates NOS3 phosphorylation at S1179, establishing a cGMP-dependent feedback loop between endothelial PDE5A and NOS3.\",\n      \"method\": \"Subcellular fractionation to caveolin-rich lipid rafts, adenoviral overexpression in vitro and in vivo, siRNA knockdown of PKG1, NOS3 activity assays, vasodilation measurements\",\n      \"journal\": \"Cardiovascular research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — reciprocal gain/loss-of-function, multiple orthogonal methods, human/mouse/bovine models\",\n      \"pmids\": [\"21421555\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"The anti-hypertrophic efficacy of PDE5A inhibition is magnitude-dependent on pressure-overload stress: sildenafil is ineffective against modest hypertrophy (low stress) but effective at higher stress levels where pathologic signaling (calcineurin, ERK-MAPK) is activated and suppressible by cGK-1, while modest hypertrophy is associated with enhanced GSK3beta/Akt phosphorylation that sildenafil further promotes.\",\n      \"method\": \"Transverse aortic constriction (TAC) mouse model at two severity levels, oral sildenafil, LV mass measurement, signaling kinase activity assays (calcineurin, ERK, GSK3beta, Akt), cGK-1 activity assay\",\n      \"journal\": \"Journal of molecular and cellular cardiology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — epistasis via dose-response stress model, multiple signaling pathway readouts\",\n      \"pmids\": [\"19159628\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Ser102 and Ser104 in PDE5A regulate its conformational flexibility and enzymatic activity; the double Ser102Ala/Ser104Ala mutant shows approximately two-fold higher cGMP hydrolysis activity than wild-type and migrates as a single band on native gels (vs. doublet for WT), indicating these serines influence phosphorylation status and allosteric regulation.\",\n      \"method\": \"Site-directed mutagenesis, in vitro cGMP hydrolysis assay with [3H]cGMP, native PAGE, GFP fusion protein expression in neuroblastoma cells, immunofluorescence\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 — in vitro activity assay with mutagenesis, single lab\",\n      \"pmids\": [\"25247292\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"miR-19a/b-3p directly targets PDE5A mRNA at its 3'UTR to suppress PDE5A expression; reduced miR-19a/b-3p levels in pressure-overload hypertrophic hearts lead to increased PDE5A and cardiac remodeling, while miR-19a/b-3p transgenic mice are protected from angiotensin II-induced cardiac hypertrophy.\",\n      \"method\": \"Luciferase reporter assay, miRNA transfection, RT-PCR, western blot, transgenic mouse model, echocardiography, pressure-volume analysis\",\n      \"journal\": \"Journal of hypertension\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — direct 3'UTR targeting confirmed by luciferase assay, validated in transgenic mouse model\",\n      \"pmids\": [\"29664809\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"The deubiquitinase OTUD1 binds directly to the GAF1 and PDEase domains of PDE5A (by Co-IP and LC-MS/MS) and removes K48-linked ubiquitin chains from PDE5A through its catalytic cysteine at position 320, thereby preventing PDE5A proteasomal degradation. Stabilized PDE5A inactivates the cGMP-PKG-SERCA2a signaling axis, dysregulating calcium handling in cardiomyocytes and promoting heart failure.\",\n      \"method\": \"LC-MS/MS, Co-immunoprecipitation, domain mapping, ubiquitination assays, NRVM knockdown/overexpression, calcium handling measurements\",\n      \"journal\": \"Biochimica et biophysica acta. Molecular basis of disease\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — Co-IP with domain mapping, LC-MS/MS, enzymatic mechanism (deubiquitination) identified with mutant\",\n      \"pmids\": [\"38185350\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"PDE5A deficiency in platelets elevates intracellular cGMP and VASP phosphorylation, and impairs platelet aggregation, ATP release, P-selectin expression, integrin alphaIIbbeta3 activation, spreading, clot retraction, phosphatidylserine exposure, calcium mobilization, and ROS production, resulting in delayed arterial and venous thrombus formation in vivo.\",\n      \"method\": \"PDE5A knockout mice, platelet aggregation assays, flow cytometry, calcium mobilization (Fluo-4 AM), western blot (VASP, ERK, AKT phosphorylation), FeCl3-induced thrombosis model, microfluidic perfusion assay\",\n      \"journal\": \"Thrombosis and haemostasis\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic KO with multiple orthogonal platelet function readouts in vitro and in vivo\",\n      \"pmids\": [\"36252813\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"Murine PDE5A isoforms A1, A2, and A3 were produced in Kluyveromyces lactis with Km, Vmax, and sildenafil inhibition kinetic constants similar to native murine enzymes, confirming that the regulatory and catalytic domains of PDE5A function properly in heterologous eukaryotic expression.\",\n      \"method\": \"Heterologous protein expression, in vitro enzymatic kinetic assay (Km, Vmax), inhibitor (sildenafil) IC50 determination\",\n      \"journal\": \"Microbial cell factories\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 — in vitro enzymatic characterization with kinetics, single lab\",\n      \"pmids\": [\"28938916\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"PDE5A overexpression in C2C12 myotubes suppresses proteasome activity, leading to ER stress and subsequent insulin resistance (reduced Akt phosphorylation and glucose uptake); PDE5A knockdown has the opposite effect. PDE5 inhibition by icariin restores proteasome activity, reduces ER stress, and rescues insulin signaling.\",\n      \"method\": \"Adenoviral overexpression/knockdown, western blot (Akt phosphorylation), 2-DG glucose uptake assay, proteasome activity assay, ER stress markers\",\n      \"journal\": \"International journal of endocrinology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — reciprocal gain/loss-of-function with multiple readouts, single lab\",\n      \"pmids\": [\"30774657\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"In zebrafish, PDE5ab (ortholog of mammalian PDE5A) is expressed in oocytes and becomes phosphorylated during human chorionic gonadotropin-induced oocyte maturation; PDE5A inhibitors (sildenafil, tadalafil) stimulate oocyte maturation through a PKG-dependent and gap junction-dependent mechanism.\",\n      \"method\": \"In situ hybridization, western blot with phospho-specific antibody, pharmacological inhibition (sildenafil, tadalafil, KT5823 PKG inhibitor, gap junction blockers), oocyte maturation assay\",\n      \"journal\": \"General and comparative endocrinology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — functional pharmacological dissection in zebrafish oocyte model, consistent with mammalian PDE5A biology\",\n      \"pmids\": [\"31654676\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"Pde5a deficiency in mice activates the cAMP-PKA signaling pathway in adipose tissue, promotes brown adipose tissue activation and white adipose tissue browning, reduces hepatic lipid accumulation, and confers resistance to diet-induced obesity with improved glucose metabolism; this indicates PDE5A regulates energy homeostasis through convergence of cGMP and cAMP signaling.\",\n      \"method\": \"Pde5a knockout mouse models, high-fat diet challenge, histological analysis, metabolic phenotyping, thermogenesis measurements, cAMP/cGMP measurement, PKA activity assay\",\n      \"journal\": \"Molecular metabolism\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic KO with multiple metabolic phenotyping methods, mechanism via cAMP-PKA pathway identified\",\n      \"pmids\": [\"40912399\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"PDE5A overexpression in striatal neurons decreases cGMP levels, reduces dendritic complexity, increases apoptosis, and enhances neuronal excitability; these effects are rescued by the PDE5 inhibitor tadalafil. In vivo stereotaxic overexpression in mouse striatum upregulates neuroinflammation gene expression and induces bipolar disorder-like behaviors.\",\n      \"method\": \"Overexpression in primary cultured striatal neurons, stereotaxic viral injection in mouse striatum, cGMP measurement, morphological analysis, electrophysiology, behavioral testing, snRNA-seq validation in human brain\",\n      \"journal\": \"Translational psychiatry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — gain-of-function with multiple orthogonal cellular and in vivo readouts plus human snRNA-seq validation\",\n      \"pmids\": [\"39695100\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"The transcription factor RUNX1 acts as a transcriptional repressor of PDE5A in vascular smooth muscle cells; exercise reduces RUNX1 expression, upregulates PDE5A, maintains VSMC contractile phenotype, and attenuates aortic dissection. VSMC-specific PDE5A overexpression recapitulates these protective effects, while PDE5A inhibition abolishes exercise benefit.\",\n      \"method\": \"RNA sequencing, gain/loss-of-function experiments (VSMC-specific overexpression), VSMC phenotype marker analysis, beta-aminopropionitrile AD mouse model, treadmill exercise intervention, chromatin immunoprecipitation (implied by transcriptional repressor identification)\",\n      \"journal\": \"Arteriosclerosis, thrombosis, and vascular biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — genetic gain/loss-of-function with clear in vivo phenotype, single lab\",\n      \"pmids\": [\"41853865\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"In Pde5a-deficient mice, loss of PDE5A results in unbalanced cAMP/cGMP ratio and metabolic reprogramming toward mixed oxidative-glycolytic metabolism under pressure overload (TAC), demonstrating that PDE5A modulates cyclic nucleotide homeostasis that controls cardiac metabolic state; pharmacological sildenafil prevents moderate but not severe TAC-induced hypertrophy in wild-type mice.\",\n      \"method\": \"Pde5a knockout mice, transverse aortic constriction, echocardiography, cAMP/cGMP measurement, lactate dehydrogenase assays, molecular marker expression, sildenafil treatment\",\n      \"journal\": \"Life science alliance\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — genetic KO with mechanistic metabolic readouts, single lab\",\n      \"pmids\": [\"40659490\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"PDE5A+ cancer-associated fibroblasts promote gastric cancer immune suppression by activating the PI3K/AKT/mTOR signaling pathway and releasing CXCL12, which engages CXCR4 on CD8+ TEX+ LAG3 T cells to recruit them and facilitate immunosuppressive tumor microenvironment; combined LAG3 blockade and PDE5A inhibitor (vardenafil) enhanced immunotherapy responses in mouse models.\",\n      \"method\": \"Single-cell RNA sequencing, spatial transcriptomics, in vitro/in vivo mechanistic studies, pathway inhibition, combination therapy in mouse models\",\n      \"journal\": \"Gut\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — scRNA-seq with in vitro/in vivo mechanistic validation, single lab\",\n      \"pmids\": [\"41115748\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Chronic vasodilation increases renal medullary PDE5A protein abundance through an AT1 receptor (angiotensin type 1)-dependent mechanism, as blockade of AT1 receptors (losartan) or ACE (enalapril) prevents the PDE5A upregulation, while mineralocorticoid receptor blockade (spironolactone) does not.\",\n      \"method\": \"Pharmacological intervention in rats (nifedipine, losartan, enalapril, spironolactone), western blot for renal medullary PDE5A protein\",\n      \"journal\": \"American journal of physiology. Regulatory, integrative and comparative physiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple pharmacological interventions defining upstream regulatory pathway, single lab\",\n      \"pmids\": [\"24068049\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Burn injury disrupts the PDE5A-cGMP-PKG signaling pathway in cardiac tissue, causing mitochondrial morphological damage, reduced mitochondrial number/area, decreased mitochondrial complex I/III/IV activity (but not complex II), reduced state 3 oxygen consumption, and decreased ATP and MnSOD activity. Sildenafil (PDE5A inhibitor) preserves mitochondrial structure and respiratory chain efficiency.\",\n      \"method\": \"Rat burn model, transmission electron microscopy, real-time qPCR (mitDNA genes), O2K-respirometry, electron transport chain activity assays, ATP measurement, sildenafil treatment\",\n      \"journal\": \"International journal of molecular sciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal mitochondrial function assays with pharmacological rescue, single lab\",\n      \"pmids\": [\"32231130\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"PDE5A is a cGMP-specific 3',5'-cyclic nucleotide phosphodiesterase that hydrolyzes cGMP to GMP; it is regulated transcriptionally (by BRAF-MEK-BRN2, RUNX1, miR-19a/b-3p, miR-30d, and cAMP/cGMP via Sp1/AP2 promoter elements), post-translationally (by OTUD1-mediated deubiquitination stabilizing it from proteasomal degradation, and by Ser102/Ser104 phosphorylation influencing its activity), and spatially (localizing to endothelial caveolae in an eNOS-dependent manner and to z-bands in cardiomyocytes); through modulation of intracellular cGMP levels it controls downstream PKG activation to regulate cardiac contractility (via troponin I phosphorylation), vascular smooth muscle tone, platelet activation and thrombus formation, melanoma cell invasion via Ca2+ signaling, adipose tissue thermogenesis via cAMP-PKA crosstalk, and neuronal excitability in striatal neurons.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"PDE5A is a cGMP-binding, cGMP-specific 3',5'-cyclic nucleotide phosphodiesterase that hydrolyzes cGMP to GMP, thereby controlling intracellular cGMP levels and downstream PKG signaling across diverse tissues including vascular smooth muscle, cardiomyocytes, platelets, adipose tissue, and neurons [PMID:9714779, PMID:20107996, PMID:36252813, PMID:40912399, PMID:39695100]. Three isoforms (PDE5A1, PDE5A2, PDE5A3) are generated from alternative promoters containing Sp1 and AP-2 elements that mediate cAMP/cGMP-dependent transcriptional feedback, while additional transcriptional regulation occurs through BRAF-MEK-BRN2 repression in melanoma and RUNX1 repression in vascular smooth muscle, and post-transcriptional control involves miR-19a/b-3p targeting of the 3'UTR [PMID:11896473, PMID:21215707, PMID:41853865, PMID:29664809]. Protein stability is regulated by OTUD1-mediated removal of K48-linked ubiquitin chains that protect PDE5A from proteasomal degradation, and phosphorylation at Ser102/Ser104 modulates conformational flexibility and catalytic activity [PMID:38185350, PMID:25247292]. In cardiomyocytes PDE5A localizes to z-bands in an eNOS-dependent manner and modulates contractility via PKG-dependent troponin I phosphorylation, while in platelets PDE5A loss elevates cGMP-VASP signaling to impair aggregation and thrombus formation, and in adipose tissue PDE5A deficiency activates cAMP-PKA–driven thermogenesis conferring resistance to diet-induced obesity [PMID:18790048, PMID:20107996, PMID:36252813, PMID:40912399].\",\n  \"teleology\": [\n    {\n      \"year\": 1998,\n      \"claim\": \"Establishing the molecular identity and enzymatic specificity of PDE5A resolved that human PDE5A1 encodes an 875-amino-acid cGMP-specific phosphodiesterase inhibitable by zaprinast and DMPPO, and that the gene maps to 4q26 with 21 exons sharing structural homology with PDE6B.\",\n      \"evidence\": \"Heterologous expression in yeast with enzymatic assay and pharmacological inhibition; genomic sequencing and FISH mapping\",\n      \"pmids\": [\"9714779\", \"9716380\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No crystal structure of full-length human PDE5A determined in these studies\", \"Substrate kinetics for different isoforms not compared\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Defining the promoter architecture and isoform regulation revealed that three PDE5A isoforms arise from two alternative promoters with Sp1/AP-2 elements mediating cAMP/cGMP-dependent transcriptional upregulation, establishing a cyclic nucleotide feedback loop at the transcriptional level.\",\n      \"evidence\": \"RACE-PCR, luciferase reporter assays, DNase I footprinting, and deletion mapping across multiple studies\",\n      \"pmids\": [\"10679249\", \"11162575\", \"11896473\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Identity of kinases or phosphatases mediating the cAMP/cGMP signal to Sp1/AP-2 not defined\", \"Relative physiological contribution of each promoter in specific tissues unknown\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Demonstrating that PDE5A is expressed and active in cardiomyocytes with eNOS-dependent z-band localization, and that its inhibition suppresses hypertrophy via PKG, established PDE5A as a spatially compartmentalized cardiac signaling node rather than solely a vascular smooth muscle enzyme.\",\n      \"evidence\": \"shRNA knockdown, DsRed-PDE5 fusion imaging, eNOS knockout mice, enzyme activity assay, video microscopy of sarcomere shortening\",\n      \"pmids\": [\"18790048\", \"19159628\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism anchoring PDE5A to z-bands not identified\", \"Whether cardiac PDE5A isoform expression differs from vascular tissues not resolved\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Mapping the full signaling cascade from PDE5A inhibition through β3-adrenergic receptor/NOS/cGMP/PKG to troponin I Ser23/24 phosphorylation defined the complete molecular pathway by which PDE5A controls cardiac contractility, ruling out PDE2/PDE3 cross-talk.\",\n      \"evidence\": \"β3-AR knockout mice, pharmacological inhibitors, sarcomere shortening video microscopy, Fura-2 Ca²⁺ imaging, TnI phosphorylation gel electrophoresis\",\n      \"pmids\": [\"20107996\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether this pathway operates identically in human cardiomyocytes not demonstrated\", \"Role of PDE5A in diastolic function not addressed\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Two discoveries expanded PDE5A's regulatory context: in endothelial cells PDE5A localizes to caveolae and engages a PKG1-NOS3 feedback loop, while in melanoma BRAF-MEK-BRN2 transcriptionally represses PDE5A to elevate cGMP-Ca²⁺ signaling and drive invasion.\",\n      \"evidence\": \"Caveolar fractionation with adenoviral overexpression/siRNA and vasodilation assays; genetic epistasis with BRAF/MEK/BRN2, cGMP/Ca²⁺ imaging, mouse colonization model\",\n      \"pmids\": [\"21421555\", \"21215707\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct BRN2 binding site on PDE5A promoter not mapped\", \"Whether caveolar localization requires direct caveolin binding not established\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Mutagenesis of Ser102/Ser104 showed these residues control PDE5A conformational flexibility and catalytic activity, with the double alanine mutant exhibiting ~2-fold higher cGMP hydrolysis, revealing an allosteric regulatory site distinct from the catalytic pocket.\",\n      \"evidence\": \"Site-directed mutagenesis, [³H]cGMP hydrolysis assay, native PAGE\",\n      \"pmids\": [\"25247292\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Identity of the kinase(s) phosphorylating Ser102/Ser104 in vivo not determined\", \"Structural basis of conformational change not resolved\", \"Single lab, no independent replication\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Identification of miR-19a/b-3p as a direct post-transcriptional repressor of PDE5A via its 3'UTR, with transgenic mice protected from cardiac hypertrophy, established microRNA control as a disease-relevant layer of PDE5A regulation.\",\n      \"evidence\": \"Luciferase 3'UTR reporter assay, miRNA transgenic mice, echocardiography, pressure-volume analysis\",\n      \"pmids\": [\"29664809\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether other miRNAs cooperate to regulate PDE5A in the heart not explored\", \"Relative contribution of miR-19a vs miR-19b not distinguished\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"PDE5A knockout platelets revealed that PDE5A is essential for normal platelet activation, demonstrating that loss of PDE5A elevates cGMP-VASP signaling and broadly impairs aggregation, secretion, integrin activation, and thrombus formation in vivo.\",\n      \"evidence\": \"PDE5A knockout mice, platelet aggregation, flow cytometry, Fluo-4 AM Ca²⁺ mobilization, FeCl₃ thrombosis model, microfluidic perfusion\",\n      \"pmids\": [\"36252813\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether PDE5A-deficient platelets have altered bleeding times not reported\", \"Contribution of individual PDE5A isoforms in platelets unknown\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Discovery that OTUD1 deubiquitinates PDE5A by removing K48-linked ubiquitin chains through Cys320, preventing proteasomal degradation and thereby inactivating cGMP-PKG-SERCA2a signaling, identified a direct post-translational mechanism controlling PDE5A protein stability in cardiomyocytes and heart failure.\",\n      \"evidence\": \"LC-MS/MS, Co-IP with domain mapping (GAF1 and PDEase domains), ubiquitination assays with catalytic-dead mutant, NRVM knockdown/overexpression, calcium handling measurements\",\n      \"pmids\": [\"38185350\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"E3 ubiquitin ligase targeting PDE5A for degradation not identified\", \"Whether OTUD1-PDE5A interaction is regulated by upstream signals unknown\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Multiple 2025 studies expanded PDE5A's systemic roles: adipose-specific Pde5a deficiency activated cAMP-PKA thermogenesis conferring obesity resistance; striatal PDE5A overexpression reduced dendritic complexity and increased neuronal excitability; RUNX1 was identified as a transcriptional repressor of PDE5A in VSMCs mediating exercise-protective effects; and Pde5a loss altered cardiac metabolic programming under pressure overload.\",\n      \"evidence\": \"Pde5a KO mice with metabolic phenotyping and cAMP/PKA assays; stereotaxic viral overexpression with electrophysiology and behavioral testing; VSMC-specific gain/loss-of-function in aortic dissection models; KO mice with TAC and metabolic readouts\",\n      \"pmids\": [\"40912399\", \"39695100\", \"41853865\", \"40659490\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether cGMP-to-cAMP crosstalk in adipose tissue involves specific PDE isoform interactions not defined\", \"Mechanism linking PDE5A to neuroinflammation gene expression in striatum not resolved\", \"Direct RUNX1 binding to PDE5A promoter requires ChIP-seq confirmation\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Key unresolved questions include the identity of the E3 ubiquitin ligase that targets PDE5A for degradation, the structural basis of Ser102/104-dependent allosteric regulation, the mechanism anchoring PDE5A to z-bands, and how PDE5A coordinates cGMP and cAMP compartmentalization across different cell types.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No full-length human PDE5A structure with regulatory domains resolved\", \"E3 ligase for PDE5A unknown\", \"Mechanism of z-band and caveolar targeting undefined\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0016787\", \"supporting_discovery_ids\": [0, 10, 14]},\n      {\"term_id\": \"GO:0140657\", \"supporting_discovery_ids\": [0]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [8]},\n      {\"term_id\": \"GO:0005856\", \"supporting_discovery_ids\": [7]},\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [7, 8]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [6, 7, 8, 9, 13, 17, 18]},\n      {\"term_id\": \"R-HSA-109582\", \"supporting_discovery_ids\": [13]},\n      {\"term_id\": \"R-HSA-1430728\", \"supporting_discovery_ids\": [17, 20]},\n      {\"term_id\": \"R-HSA-392499\", \"supporting_discovery_ids\": [12]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\n      \"OTUD1\",\n      \"NOS3\",\n      \"PKG1\",\n      \"BRN2\",\n      \"RUNX1\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}